Table 3.

Associations of cardiac biomarkers and incident HF in the CRIC Study

Cardiac BiomarkerModel 1aModel 2bModel 3c
Hazard Ratio (95% Confidence Interval)P ValueHazard Ratio (95% Confidence Interval)P ValueHazard Ratio (95% Confidence Interval)P Value
Continuous predictors
 Log(hsTnT) per 1 SD (1.12) increase1.60 (1.36 to 1.88)<0.0011.50 (1.27 to 1.78)<0.0011.27 (1.07 to 1.52)0.008
 Log(NT-proBNP) per 1 SD (1.39) increase2.30 (1.99 to 2.66)<0.0012.11 (1.80 to 2.47)<0.0011.99 (1.69 to 2.35)<0.001
Categorical predictorsd
 hsTnT, pg/ml (reference: undetectable)
  >5–9.31.75 (0.96 to 3.22)<0.0011.96 (1.02 to 3.79)<0.0011.98 (1.03 to 3.83)0.001
  >9.3–15.02.47 (1.38 to 4.39)2.70 (1.44 to 5.05)2.51 (1.34 to 4.71)
  >15.0–26.52.72 (1.52 to 4.88)2.96 (1.57 to 5.59)2.47 (1.31 to 4.66)
  >26.54.85 (2.68 to 8.80)4.77 (2.49 to 9.14)3.71 (1.93 to 7.13)
 NT-proBNP, pg/ml (reference: ≤47.6)
  >47.6–95.82.71 (1.28 to 5.75)<0.0012.71 (1.23 to 5.98)<0.0012.57 (1.17 to 5.68)<0.001
  >95.8–188.84.11 (1.99 to 8.50)3.72 (1.72 to 8.04)3.41 (1.58 to 7.39)
  >188.8–433.05.73 (2.80 to 11.74)5.47 (2.55 to 11.74)4.76 (2.21 to 10.23)
  >433.011.83 (5.75 to 24.34)9.57 (4.40 to 20.83)8.07 (3.70 to 17.64)
  • a Model 1 adjusted for age, sex, race/ethnicity, clinical center, diabetes status, self-reported cardiovascular disease at baseline, current smoking, alcohol use, log(24-hour urine total protein excretion), eGFR, systolic BP, body mass index, LDL, and HDL.

  • b Model 2 adjusted for model 1 variables plus hemoglobin, angiotensin-converting enzyme/angiotensin receptor blocker use, diuretic use, β-blocker use, serum phosphorus, log(PTH), and log(FGF23).

  • c Model 3 adjusted for model 2 variables plus the alternative cardiac biomarker (e.g., adjusted for NT-proBNP and hsTnT in the models and vice versa).

  • d Detectable levels of hsTnT were divided into quartiles; NT-proBNP categories were defined by quintiles.